Publications by authors named "William H Meyer"

64Publications

Improving Outcomes for Patients With Pulmonary Metastatic Ewing Sarcoma.

Authors:
William H Meyer

J Clin Oncol 2019 12 21;37(34):3173-3175. Epub 2019 Oct 21.

University of Oklahoma Health Sciences Center, Oklahoma City, OK.

View Article and Find Full Text PDF
December 2019

Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care.

Authors:
William H Meyer

Lancet Oncol 2019 11 24;20(11):1476-1477. Epub 2019 Sep 24.

Jimmy Everest Section of Pediatric Hematology/Oncology, Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA. Electronic address:

View Article and Find Full Text PDF
November 2019

Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group.

Cancer 2019 08 8;125(15):2602-2609. Epub 2019 May 8.

Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.

View Article and Find Full Text PDF
August 2019

Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

J Clin Oncol 2018 Oct 23:JCO2018789388. Epub 2018 Oct 23.

David O. Walterhouse, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; Donald A. Barkauskas, University of Southern California, Los Angeles; David Hall, Children's Oncology Group, Monrovia, CA; Andrea Ferrari, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan; Gian Luca De Salvo, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua; Gianni Bisogno, University of Padua, Padova, Italy; Ewa Koscielniak, Olgahospital, Stuttgart; Guido Seitz, University Hospital, Marburg, Germany; Michael C.G. Stevens, Royal Hospital for Children, Bristol, United Kingdom; Hélène Martelli, Assistance Publique-Hôpitaux de Paris, Hopital Bicetre, Le Kremlin-Bicetre; Christophe Bergeron, Centre Léon Bérard, Lyon; Veronique Minard-Colin, Gustave Roussy, Villejuif, France; David A. Rodeberg, East Carolina University, Greenville, NC; Margarett Shnorhavorian and Douglas S. Hawkins, Seattle Children's Hospital, University of Washington; Douglas S. Hawkins, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA; Roshni Dasgupta and John C. Breneman, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; James R. Anderson, Merck Research Laboratories, North Wales, PA; and William H. Meyer, University of Oklahoma School of Medicine, Oklahoma City, OK.

View Article and Find Full Text PDF
October 2018

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

J Clin Oncol 2018 09 9;36(27):2770-2777. Epub 2018 Aug 9.

Douglas S. Hawkins, Erin R. Rudzinski, and Margarett Shnorhavorian, Seattle Children's Hospital, Seattle, WA; Yueh-Yun Chi and Jing Tian, University of Florida, Gainesville, FL; James R. Anderson, Merck Research Laboratories, North Wales, PA; Carola A.S. Arndt, Mayo Clinic, Rochester, MN; Lisa Bomgaars, Texas Children's Hospital; Andrea Hayes-Jordan, MD Anderson Cancer Center, Houston; Stephen X. Skapek, University of Texas Southwestern, Dallas, TX; Sarah S. Donaldson, Lynn Million, and Sheri L. Spunt, Stanford University School of Medicine, Stanford; Leo Mascarenhas and David M. Parham, Children's Hospital of Los Angeles, Los Angeles; Jeannine S. McCune, City of Hope, Duarte, CA; Mary Beth McCarville, St Jude Children's Research Hospital, Memphis, TN; Geoff McCowage, Children's Hospital at Westmead, Westmead, New South Wales, Australia; Carol D. Morris, Johns Hopkins University, Baltimore, MD, David A. Rodeberg, East Carolina University, Greenville, NC; Lisa A. Teot, Boston Children's Hospital; Torunn I. Yock, Massachusetts General Hospital, Boston, MA; Suzanne Wolden, Memorial Sloan Kettering Cancer Center, New York, NY; and William H. Meyer, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

View Article and Find Full Text PDF
September 2018

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Pediatr Blood Cancer 2017 Dec 18;64(12). Epub 2017 May 18.

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California.

View Article and Find Full Text PDF
December 2017

Diffuse Marrow Involvement in Metastatic Osteosarcoma: An Unusual Presentation.

J Oncol Pract 2017 06 24;13(6):401-403. Epub 2017 Apr 24.

The Children's Hospital, University of Oklahoma; and College of Medicine, University of Oklahoma, Oklahoma City, OK.

View Article and Find Full Text PDF
June 2017

Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Pediatr Blood Cancer 2017 Sep 23;64(9). Epub 2017 Mar 23.

Division of Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article and Find Full Text PDF
September 2017

Regarding Beau.

Authors:
William H Meyer

J Clin Oncol 2016 08 6;34(22):2669-70. Epub 2016 Jun 6.

University of Oklahoma Health Sciences Center, Oklahoma City, OK.

View Article and Find Full Text PDF
August 2016

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

J Clin Oncol 2016 Jan 26;34(2):117-22. Epub 2015 Oct 26.

Brenda J. Weigel, University of Minnesota, Minneapolis; Carola A.S. Arndt, Mayo Clinic, Rochester, MN; Elizabeth Lyden, Nebraska Medical Center, Omaha, NE; James R. Anderson, Frontier Science and Technology Research Foundation, Madison, WI; William H. Meyer, University of Oklahoma Health Sciences Center, Oklahoma City, OK; David M. Parham, Children's Hospital of Los Angeles, Los Angeles, CA; David A. Rodeberg, East Carolina University, Greenville, NC; Jeff M. Michalski, Washington University School of Medicine, St Louis, MO; and Douglas S. Hawkins, University of Washington, Seattle, WA.

View Article and Find Full Text PDF
January 2016

Progress Born From a Legacy of Collaboration.

J Clin Oncol 2015 Sep 24;33(27):2935-7. Epub 2015 Aug 24.

St Jude Children's Research Hospital, Memphis, TN.

View Article and Find Full Text PDF
September 2015

Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

J Clin Oncol 2014 Nov 29;32(31):3547-52. Epub 2014 Sep 29.

David O. Walterhouse, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL; Alberto S. Pappo, Saint Jude Children's Research Hospital, Memphis, TN; Jane L. Meza, James R. Anderson, University of Nebraska Medical Center College of Public Health, Omaha, NE; John C. Breneman, Children's Hospital Medical Center, Cincinnati; Timothy P. Cripe, Nationwide Children's Hospital, Columbus, OH; Andrea Hayes-Jordan, MD Anderson Cancer Center, Houston, TX; David M. Parham, William H. Meyer, University of Oklahoma School of Medicine, Oklahoma City, OK; Douglas S. Hawkins, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.

View Article and Find Full Text PDF
November 2014